CLX

CLOROX CO

Consumer Defensive | Large Cap

$1.03

EPS Forecast

$1,887

Revenue Forecast

The company already released most recent quarter's earnings. We will publish our AI's next quarter's forecast around 2026-12-31

Clorox’s FY26 Finish Line: GOJO Deal Boosts Portfolio, ERP Headwinds Weigh on EPS

By a finance writer who loves a tidy balance sheet and a well-timed pun

Executive snapshot: CLX pivots amid a GOJO integration and a big ERP year

For CLX, the ticker that has long been a household name in the aisle, the fourth quarter and fiscal year 2026 unfolded with a mix of strategic lift and operational drag. On the one hand, Clorox completed the acquisition of GOJO Industries, expanding into Purell and a broader health and hygiene portfolio. On the other hand, the company logged margin compression tied to volume headwinds, an inventory step-up from the GOJO deal, and ERP migration effects. The standout figures: net sales declined 2% to about $1.95 billion; diluted EPS fell 50% to $1.34, while adjusted EPS slipped 42% to $1.66. Those numbers sit against management commentary that the quarter was “in line with expectations,” with a note that the ERP transition and GOJO inventory step-up each shaved roughly 150 basis points from gross margin.

In the wake of the GOJO acquisition—renamed Clorox Purell in spirit if not in legal footnotes—the company also reaffirmed a longer view: navigate a challenging macro environment, complete a U.S. ERP implementation, and invest in digital capabilities to support a path back to organic growth. The press release stresses that non-GAAP metrics are included and that the team expects continued volatility as the base business absorbs the ERP-related lapses.

What happened, numbers in plain English

  • Net sales: down 2% to $1.95 billion. The GOJO acquisition contributed roughly 10 points to the topline, but organic sales declined 13% due to lapping ERP shipments—roughly 13.5 points of impact.
  • Gross margin: contracted 520 basis points to 41.3% from 46.5%, driven by lower volume, the inventory step-up tied to the GOJO deal, higher commodity costs, and higher manufacturing and logistics costs. ERP shipment comparisons and the GOJO inventory step-up each shaved about 150 basis points.
  • EPS: diluted EPS declined 50% to $1.34; adjusted EPS fell 42% to $1.66. The company notes that ERP-related shipment comparisons and GOJO-related items contributed to softer results and that the dynamic was partially offset by benefits from investments in digital capabilities and productivity.
  • Non-GAAP measures & commentary: the press release emphasizes Non-GAAP measures and notes line items for reconciliation; management highlighted disciplined execution and a strengthened foundation as the company advanced the GOJO integration and ERP modernization.

“Our fourth-quarter results were in line with our expectations and reflect disciplined execution in a dynamic environment,” chair and CEO Linda Rendle said. “We strengthened our business despite continued consumer and macroeconomic pressures. We expanded our portfolio through the acquisition of GOJO Industries, completed our U.S. ERP implementation, and continued to modernize systems and processes that underpin operations, while advancing our digital capabilities.”

Outlook and what it portends for the near term

As Clorox looks to fiscal year 2027, the guidance is tinted with caution: the operating environment remains challenging, cost volatility persists, and the consumer remains value-conscious. Yet the tone is constructive—management frames the GOJO acquisition and ERP modernization as foundational to long-term value creation and a platform for returning to organic growth.

The lack of an explicit revenue forecast in the release suggests the company will rely on its ongoing efficiency programs and portfolio optimization to drive results in a volatile backdrop. Investors will be weighing whether the margin recovery can outpace ongoing commodity and logistics pressures, and whether the integration of GOJO can yield higher-margin sources like essential hygiene solutions in a more stable post-integration period.

Implications for Clorox peers and the sector

The Clorox story is increasingly a tale of two eras: one where acquisitions broaden the product portfolio and fuel a longer-term growth narrative, and another where ERP migrations and inventory normalization weigh on near-term profitability. For sector peers, this signals a familiar playbook: if you’re weaving in a large-scale ERP push or snapping up a high-myriad brand, the near-term EPS may wobble as the integration overhang dissipates. The good news—if you can weather the ERP storm, the combination of a stronger portfolio and digital-enabled operations can unlock meaningful margin expansion down the line.

Analysts will likely watch not just EPS and revenue trajectory, but also how quickly the acquired GOJO business contributes to steady cash flow and how the company manages inflationary pressures in production and logistics. The absence of a clear near-term revenue forecast leaves a question mark on timing, but the strategic move toward a more diversified hygiene portfolio could make CLX a more resilient benchmark should consumer sentiment swing back toward premium, essential categories.

Bottom line: resilience through repositioning

Clorox’s FY26 results reflect a company balancing the pull of a transformative acquisition with the push of a large ERP rollout. The EPS contraction is a function of one-time integration costs, inventory steps, and migration-related revenue volatility, not a permanent re-pricing of its products. If the company can navigate the rest of calendar 2027 with a stabilized margin trajectory and a steadier top line, the GOJO portfolio and improved digital backbone could offer a meaningful path back to sustained EPS growth and a more confident revenue forecast for investors who are weighing CLX against its sector peers.

Note: The company highlighted Non-GAAP measures at the end of the press release. This summary reflects the reported Q4 and FY26 results, the GOJO acquisition’s impact, and the ERP integration dynamics. For investors, the key metrics to monitor going forward include EPS (GAAP and adjusted), revenue trajectory, gross margin progression, and the pace at which GOJO-related benefits and ERP clean-up flow through to the bottom line.